DARE DARE BIOSCIENCE INC Product Launches 8-K Filing 2023 - Phase 1 Clinical Study Results Dar Bioscience, Inc. announced topline results from the Phase 1 clinical study of DARE-PDM1, a treatment for primary dysmenorrhea, showing promising efficacy and safety profiles.Get access to all SEC 8-K filings of the DARE BIOSCIENCE INC